Multicenter, double-blind, placebo-controlled trial of triamcinolone acetonide nasal aerosol in the treatment of perennial allergic rhinitis. 1990

S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
Department of Clinical Research, Rorer Central Research, Horsham, PA 19044.

In a double-blind study involving 205 patients with perennial allergic rhinitis, statistically significantly greater symptomatic improvements were evident following the administration of 200 micrograms/day triamcinolone acetonide aerosol than following placebo. These improvements were evident as early as week 1 and were sustained throughout the 12-week study. They were accompanied by greater reductions in nasal eosinophils. Triamcinolone acetonide aerosol was well tolerated and had no effect on serum cortisol levels.

UI MeSH Term Description Entries
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D012221 Rhinitis, Allergic, Perennial Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc. Rhinitis, Allergic, Nonseasonal
D014222 Triamcinolone Acetonide An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions. Azmacort,Cinonide,Kenacort A,Kenalog,Kenalog 40,Tricort-40,Acetonide, Triamcinolone,Tricort 40,Tricort40
D015337 Multicenter Studies as Topic Works about controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children. Multicenter Trials,Multicentre Studies as Topic,Multicentre Trials,Multicenter Trial,Multicentre Trial,Trial, Multicenter,Trial, Multicentre,Trials, Multicenter,Trials, Multicentre

Related Publications

S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
January 1995, Clinical therapeutics,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
January 1994, Clinical therapeutics,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
November 1991, Annals of allergy,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
July 1993, The Journal of allergy and clinical immunology,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
January 1996, Clinical therapeutics,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
January 1995, Clinical therapeutics,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
January 1962, The Journal of allergy,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
February 1990, Annals of allergy,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
June 2001, Acta oto-laryngologica,
S Spector, and E Bronsky, and P Chervinsky, and G Lotner, and J Koepke, and J Selner, and D Pearlman, and D Tinkelman, and S Weakley, and V Alderfer
April 1991, Annals of allergy,
Copied contents to your clipboard!